Adial Pharmaceuticals (ADIL) Company Overview

Completion enables the End-of-Phase 2 (EOP2) interaction with the FDA on the design of the Phase 3 program and is expected to facilitate ongoing partnership discussions

GLEN ALLEN, Va., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 12150931 was issued on November 26, 2024 by the United States Patent and Trademark Office, expanding the Company's intellectual property coverage.

Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Glen Allen, VA, October 23, 2024 – PRISM MediaWire – Adial Pharmaceuticals, Inc.

GLEN ALLEN, Va., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York.

GLEN ALLEN, Va., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced database lock for the pharmacokinetics study of AD04, the Company's lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day).

GLEN ALLEN, Va., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the second quarter of 2024.

Adial Pharmaceuticals (NASDAQ:ADIL) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company announced an update on its AD04 study. Adial Pharmaceuticals notes that AD04 is progressing to a second cohort in its pharmacokinetics study.

Making millions through the stock market is only possible in a few ways. Investors need one of these three things: Massive sums of capital to begin with Decades of time and more modest sums of capital More modest sums of capital and a combination of risk and luck We will be talking about the latter today: seven stocks you can buy for $2 that can 10X by 2025.